ZFIN ID: ZDB-FISH-150901-63
Fish name: WT + MO3-pkd2
Genotype: WT
Targeting Reagent: MO3-pkd2
HUMAN DISEASE MODELED by WT + MO3-pkd2
Human Disease Conditions Citations
autosomal dominant polycystic kidney disease standard conditions (2)
GENE EXPRESSION
Gene expression in WT + MO3-pkd2
RNA expression
Expressed Gene Structure Conditions Figures
hexim1 standard conditions Fig. 4 from Sun et al., 2019
il1b chemical treatment: pharmaceutical Fig. S2 from Chang et al., 2011
standard conditions Fig. S2 from Chang et al., 2011
ins standard conditions text only from Fogelgren et al., 2011
lcp1 standard conditions Fig. 4 with image from Chang et al., 2017
chemical treatment by environment: metformin Fig. 4 with image from Chang et al., 2017
lft1 standard conditions text only from Fogelgren et al., 2011
lft2 standard conditions text only from Fogelgren et al., 2011
mpx standard conditions Fig. 4 with image from Chang et al., 2017
chemical treatment by environment: metformin Fig. 4 with image from Chang et al., 2017
myl7 standard conditions text only from Fogelgren et al., 2011
p2rx7 chemical treatment: pharmaceutical Fig. 6 from Chang et al., 2011
standard conditions Fig. 1Fig. 6 from Chang et al., 2011
pkd2 standard conditions Fig. 1 from Paavola et al., 2013
spaw standard conditions text only from Fogelgren et al., 2011
wt1a standard conditions Fig. 4 with image from Fogelgren et al., 2011
Reporter gene expression No data available
PHENOTYPE
Phenotype in WT + MO3-pkd2
Phenotype Conditions Figures
brain hydrocephalic, abnormal standard conditions Fig. 6 from Sussman et al., 2014
Fig. 9 with image from Rothschild et al., 2011
Fig. 8 from Giamarchi et al., 2010
calmodulin-dependent protein kinase activity decreased occurrence, abnormal standard conditions Fig. 8 with image from Rothschild et al., 2011
calmodulin-dependent protein kinase activity decreased rate, abnormal standard conditions Fig. 7 with image from Francescatto et al., 2010
cell proliferation involved in pronephros development increased occurrence, abnormal standard conditions Fig. 4 from Chang et al., 2011
cloacal chamber ciliary basal body present, normal standard conditions Fig. 9 with image from Rothschild et al., 2011
cloacal chamber cilium decreased amount, abnormal standard conditions Fig. 9 with image from Rothschild et al., 2011
cloacal chamber cilium decreased length, abnormal standard conditions Fig. 9 with image from Rothschild et al., 2011
determination of heart left/right asymmetry disrupted, abnormal standard conditions Fig. 8 from Giamarchi et al., 2010
determination of left/right symmetry process quality, abnormal standard conditions text only from Fogelgren et al., 2011
gut edematous, abnormal standard conditions Fig. S1 from Chang et al., 2011
head hydrocephalic, abnormal standard conditions Fig. 4 from Sun et al., 2019
heart edematous, abnormal standard conditions Fig. 8 from Giamarchi et al., 2010
heart mislocalised, abnormal standard conditions Fig. 8 from Giamarchi et al., 2010
heart looping disrupted, abnormal standard conditions Fig. 8 from Giamarchi et al., 2010
hypoblast calcium-mediated signaling process quality, abnormal standard conditions Fig. 4 with image from Yuan et al., 2015
inner ear posterior-most region increased distance pronephric duct anterior-most region, abnormal standard conditions Fig. 9 with image from Rothschild et al., 2011
Kupffer's vesicle calcium-mediated signaling process quality, abnormal standard conditions Fig. 2 with image from Yuan et al., 2015
Kupffer's vesicle cilium movement process quality, normal standard conditions Fig. 3 with image from Yuan et al., 2015
post-vent region curved, abnormal standard conditions Fig. 4 with image from Fogelgren et al., 2011
post-vent region curved dorsal, abnormal standard conditions Fig. 6 with image from Arif Pavel et al., 2016
Fig. 9 with image from Rothschild et al., 2011
Fig. 1 from Yuan et al., 2009
post-vent region increased curvature, abnormal standard conditions Fig. 6 with image from Arif Pavel et al., 2016
Fig. 1 with imageTable 2 from Sun et al., 2004
pronephric duct anatomical region has extra parts of type leukocyte, abnormal standard conditions Fig. 4 with image from Chang et al., 2017
pronephric duct anatomical region has number of leukocyte, ameliorated chemical treatment by environment: metformin Fig. 4 with image from Chang et al., 2017
pronephric duct distal region obstructed, abnormal standard conditions Fig. 9 with image from Rothschild et al., 2011
pronephric duct epithelial cell proliferation increased occurrence, abnormal standard conditions Fig. 3 with image from Chang et al., 2017
pronephric duct epithelial cell proliferation occurrence, ameliorated chemical treatment by environment: metformin Fig. 3 with image from Chang et al., 2017
pronephric glomerulus increased size, abnormal standard conditions Fig. 8 with image from Sullivan-Brown et al., 2008
pronephric tubule shape, normal standard conditions Fig. 8 with image from Sullivan-Brown et al., 2008
pronephros cystic, abnormal standard conditions Fig. 4 from Sun et al., 2019
Fig. 6 from Sussman et al., 2014
Fig. 8 from Giamarchi et al., 2010
Fig. 1 with imageTable 2 from Sun et al., 2004
pronephros anterior region structure, abnormal standard conditions Fig. 9 with image from Rothschild et al., 2011
pronephros anterior region truncated, abnormal standard conditions Fig. 9 with image from Rothschild et al., 2011
pronephros morphogenesis decreased process quality, abnormal standard conditions Fig. 3 with imageFig. 4 with image from Chang et al., 2017
protein autophosphorylation decreased occurrence, abnormal standard conditions Fig. 7 with image from Francescatto et al., 2010
trunk curved dorsal, abnormal standard conditions Fig. 3 from Bouvrette et al., 2010
trunk increased curvature, abnormal standard conditions Fig. 6 from Sussman et al., 2014
whole organism curved dorsal, abnormal standard conditions Fig. 4 from Sun et al., 2019
whole organism Ab1-prkaa labeling increased amount, abnormal chemical treatment by environment: metformin Fig. 5 with image from Chang et al., 2017
whole organism Ab2-prkaa labeling increased amount, abnormal chemical treatment by environment: metformin Fig. 5 with image from Chang et al., 2017
whole organism increased curvature, abnormal standard conditions Fig. 8 from Giamarchi et al., 2010
whole organism cAMP-dependent protein kinase activity increased occurrence, abnormal chemical treatment by environment: metformin Fig. 5 with image from Chang et al., 2017

CITATIONS  (16)